CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise 10b5-1 | +1,113 | $48.51 | $54K | 101,951 |
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Sale 10b5-1 | −38,730 | $82.30 | $3.2M | 63,221 |
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −23,370 | 30,047 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −9,307 | 32,019 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −2,817 | 6,199 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −1,113 | 28,934 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Incentive Stock Option (Right to Buy) 10b5-1 | −188 | 6,011 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −822 | 31,197 | ||
| 2026-06-24 | Lee Sung EVP, Chief Financial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −1,113 | 27,821 | ||
| 2026-06-23 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-06-23 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $79.51 | $278K | 153,902 |
| 2026-06-23 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 40,886 | ||
| 2026-06-15 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $70.46 | $528K | 385,330 |
| 2026-06-09 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-06-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $67.98 | $238K | 153,902 |
| 2026-06-09 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 44,386 | ||
| 2026-06-01 | Kaye Edward M. MD Director | Sale 10b5-1 | −2,933 | $76.09 | $223K | 10,283 |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 73,555 |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $74.08 | $1.1M | 58,555 |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 39,000 |
Page 6 of 22 · 429 trades